Pfizer, Inc.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
企業詳細臨床日程
銘柄カテゴリー
臨床日程
- 2026年8月23日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting - 2026年8月28日予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
企業詳細 - 2026年8月30日予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
企業詳細 - 2026年9月予定
ABBV第2相がん・腫瘍Active Not Recruiting AbbVie Inc.
Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Recruiting AstraZeneca PLC
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
企業詳細 - 2026年9月予定
AZN第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
企業詳細 - 2026年9月予定
AZN第2相がん・腫瘍Enrolling By Invitation AstraZeneca PLC
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
企業詳細 - 2026年9月予定
GILD第2相感染症・ワクチンActive Not Recruiting Gilead Sciences, Inc.
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
企業詳細 - 2026年9月予定
LLY第2相糖尿病・代謝Active Not Recruiting Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
企業詳細 - 2026年9月予定
MAZE第2相心臓・循環器Recruiting Maze Therapeutics, Inc.
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
企業詳細 - 2026年9月予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
企業詳細 - 2026年9月予定
SNDX第2相がん・腫瘍Active Not Recruiting Syndax Pharmaceuticals, Inc.
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
企業詳細 - 2026年9月1日予定
NVO第2相糖尿病・代謝Recruiting Novo Nordisk A/S
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
企業詳細 - 2026年9月1日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting Pfizer, Inc.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
企業詳細 - 2026年9月2日予定
MRK第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
企業詳細 - 2026年9月5日予定
MRK第2相免疫・炎症Active Not Recruiting Merck & Company, Inc.
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
企業詳細 - 2026年9月15日予定
PFE第1相・第2相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
企業詳細
